SNCA and Parkinson disease: This team targeted the reduction of α-synuclein aggregation again [143] using primary dendritic cell-derived, RVG-modified exosomes encapsulating the therapeutic molecule shRNA-MCs, which were specifically delivered to the brains of PD mice by intravenous injection and attenuated α-synuclein aggregation, reducing the loss of dopaminergic neurons and thus improving PD-related symptoms.